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The processes of aging and cancer share many 
characteristics despite their opposing phenotypes of 
senescence versus immortalisation [1]. In both cases for 
example there is accumulation of DNA damage and the 
loss of genomic integrity [1, 2]. Two major players 
which impinge upon chromatin structure and the 
maintenance of genomic integrity in mammalian 
systems are p53 [3-6] and SIRT1 [7-9]. Reciprocal 
regulation occurs between SIRT1 and p53 in which 
SIRT1 binds and de-acetylates activated p53 [10-12] 
whilst activated p53 down-regulates SIRT1 translation 
via miR-34a  [13].  The p53 protein is best known as  a  
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Abstract: Senescence  is blocked  in human cervical keratinocytes  infected with high  risk human papillomavirus  (e.g. HPV
type16).  Viral  oncoproteins  HPV  E6  and  HPV  E7  access  the  cell  cycle  via  cellular  p53  and  retinoblastoma  proteins
respectively. Previously we have shown that HPV E7, not HPV E6, is also responsible for cervical cancer cell survival (SiHa
cells; HPV type16). We now present evidence that SIRT1, an aging‐related NAD‐dependent deacetylase, mediates HPV E7




propose  that elevated SIRT1  levels  (induced by HPV E7) attenuate p53 pro‐apoptotic capacity via  its de‐acetylation. Our
discovery  that  HPV  E7  up‐regulates  SIRT1  links  a  clinically  important  oncogenic  virus  with  the  multi‐functional  SIRT1




tumour suppressor but is becoming increasingly 
recognized as a factor also involved in senescence and 
aging [14, 15]. Conversely SIRT1, one of seven 
mammalian sirtuins and an NAD-dependent de-
acetylase [16], first emerged as a potential anti-aging 
factor (reviewed in [17, 18]) but is now also implicated 
in a number of age-related disease processes including 
tumour development (which it suppresses) [9, 19] and 
cancer cell survival (which it supports) [20].  
 
The yeast model provided the initial evidence linking 
SIRT1 with aging. Thus Sir2, the ancestral homologue 
of SIRT1, is a yeast NAD-dependent deacetylase and 
longevity factor [16, 17]. In budding yeast Sir2-
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mediated silencing at rDNA loci is crucial for chromatin 
compaction and suppresses homologous recombination 
[16]. In this way Sir2 suppresses the formation and 
accumulation of extra-chromosomal rDNA circles, one 
of the primary causes of yeast aging [21]. Sir2 thus 
functions as a longevity factor in yeast in which it also 
silences mating type loci, is responsive to growth 
conditions and calorie restriction [16]. Recent evidence 
now indicates that, in mammals, its homologue SIRT1 
also functions as a longevity factor [8, 17, 22-24] and is 
responsive to diverse stresses many of which also 
activate the p53 tumour suppressor [8, 17, 25, 26].  
 
Much of our understanding of the molecular biology of 
cancer derives from early studies in which DNA tumour 
viruses were employed and the mechanisms by which 
they induce cell transformation from normal to 
cancerous growth were elucidated. Indeed studies with 
DNA tumour viruses led to the initial discovery of p53, 
the major tumour suppressor in humans [27]. One of 
these viruses was the human papillomavirus (HPV) 
which targets p53 via the HPV E6 protein. High risk 
HPV types are now recognised as the cause of human 
cervical cancer (see for example [28]) and responsible 
for some 500,000 newly diagnosed cases worldwide 
each year. High risk HPV types include HPV16 and 
HPV18 [28]. Although vaccination strategies are now 
employed to protect uninfected children, there remain 
millions of HPV-infected women who are at risk of 
developing cervical cancer. The switch from HPV 
latency to malignancy is poorly understood. This 
transition appears to involve integration of the viral 
episome into the host cell genome together with 
enhanced expression of two viral oncoproteins HPV E6 
and HPV E7 [29]. Presumably some event favours 
stable integration of viral chromatin into host 
chromatin. Understanding this crucial switch may 
enable the development of novel therapies designed to 
protect HPV-positive patients from progression to 
malignancy.  
 
HPV E6 and E7 are expressed as bicistronic mRNA. In 
this current work we have exploited a previous 
unexpected observation, namely that in HPV16-positive 
SiHa cells it is possible to selectively and individually 
silence E6 and E7 by RNA interference (RNAi) despite 
the contiguous nature of their mRNAs [30]. Here we 
have confirmed and extended this important 
observation, and studied the individual effects of HPV 
E6 and E7 expression in human cervical cancer cells 
(SiHa) and in primary human epithelial keratinocytes 
(the cell type infected by HPV in vivo). 
 
It is already established that HPV16 E6 targets the p53 
protein for rapid degradation with consequential loss of 
p53 tumour suppressor functions, including 
maintenance of chromosomal integrity. We have now 
discovered that the second HPV viral oncogene, HPV16 
E7, targets SIRT1. Specifically we demonstrate (i) that 
exogenous expression of HPV E7 (but not HPV E6) in 
primary human keratinocytes induces abnormally high 
levels of the SIRT1 protein, similar to those observed in 
human cervical cancer cells, and (ii) that HPV E7 (but 
not HPV E6) is required to maintain the abnormally 
high levels of SIRT1 protein expressed in cervical 
cancer cells. The ability of HPV E7 to up-regulate 
SIRT1 appears to be linked with HPV E7-mediated 
suppression of apoptosis in cervical cancer cells [30] 
since our current work also demonstrates that SIRT1 
suppresses apoptosis in SiHa cells. In addition to up-
regulating SIRT1 we show that HPV E7 induces global 
site-specific histone H3 modifications and, in synergy 
with the kinase aurora B, up-regulates the anti-apoptotic 
survivin protein. These various changes are predicted to 
affect chromatin structure and to promote cell survival. 
 
Our discovery that HPV E7 influences the expression of 
SIRT1 provides the first link between an oncogenic 
virus and the aging-related SIRT1 protein, and enables 
access to diverse SIRT1-dependent cellular regulatory 
systems. This link may open the way for a more in-
depth understanding of the inter-relationships between 
aging and cancer. It may also provide insight into the 
mechanism of chromosomal re-distribution during the 
switch from latent to malignant HPV viral infection, 
and also for the maintenance of HPV-induced 
malignancy. 
 
RESULTS AND DISCUSSION 
 
Individual knock-down of HPV16 E6 and E7 in SiHa 
cells 
 
For this study we exploited the ability of RNAi to 
separately knockdown the viral oncogenes HPV16 E6 
and HPV16 E7 in HPV16-positive SiHa cervical cancer 
cells. Individual knockdown of HPV E6 and E7 by their 
respective siRNAs was verified by quantitative RT-PCR 
(Figure 1A, left panel), thus confirming our previous 
observations [30].  This effect appears peculiar to SiHa 
cells since similar individual knock-down of E6 and E7 
was not obtained for HPV16-positive CaSki cervical 
cancer cells in which E7 siRNA induced knock-down of 
both HPV E6 and E7 expression (Figure 1A, right 
panel, asterix).  
 
The mechanistic basis for the differential specificity of 
E7 siRNA in SiHa versus CaSki cells is at present 
unclear. However, it is noteworthy that the bicistronic 
E6/E7 transcripts produced in SiHa and CaSki cells 
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differ in their junctional organisation [29, 31] and in 
their predicted secondary structures [29]. Secondary 
structure could affect accessibility and/or progression of 
RNAi-associated machinery along the bicistronic trans-
cript. Thus it may be that an E6/E7 mRNA boundary 
effect is imposed by RNA secondary structure which 
segregates E6 and E7 RNAi-mediated silencing of the 
bicistronic transcript in SiHa cells. 
 
RNAi-mediated knockdown of HPV E6 and E7 in SiHa 
cells was further investigated using additional siRNAs 












































obtained without effect on E6 mRNA levels using two 
independent E7 siRNAs (E7 and E7b siRNAs, Figure 
1B and 1C). Conversely, two of three E6 siRNAs 
selectively targeted E6 mRNA for degradation without 
effect on E7 mRNA (E6 and E6b siRNAs, Figure 1B 
and 1C). Interestingly, a third E6 siRNA (E6c), 
designed to target the junction region of the E6/E7 bi-
cistronic transcript, induced knock down of both E6 and 
E7 mRNA sequences (Figure 1B and 1C). Overall these 
results support the concept of a boundary effect 
influencing RNAi-mediated degradation at the HPV 













































protein.    (A) mRNA qRT‐PCR determinations  48h post‐transfection  as  indicated, mean  ±  s.d.  of  three  determinations. Asterix  indicates
differential effect of E7 siRNA on E6 mRNA  levels  in SiHa versus CaSki cells. (B) Relative positions of siRNA sequences along the bicistronic
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HPV E6 is known to target p53 for degradation and, as 
expected, E6 knockdown resulted in elevated p53 
protein levels and up-regulation of p53-dependent p21 
expression (Figure 1D; see also [30]) but had no effect 
on the phosphorylation status of the retinoblastoma 
protein (Rb; Figure 1E). HPV E7 on the other hand is 
known to induce hyperphosphorylation of Rb and, as 
expected, depletion of E7 via E7 siRNA resulted in loss 
of hyper-phosphorylated Rb (Rb*, Figure 1E; see also 
[30]) but was without effect upon p53 protein levels or 
p21 expression (Figure 1D). These combined 
observations are absolutely consistent with selective and 
individual RNAi-mediated knock-down of HPV E6 and 
E7 in human cervical cancer SiHa cells.  
 
 
E7 silencing has site–specific effects on global 
histone H3 modifications  
 
We next examined the epigenetic effects of HPV E6 
and E7 upon global modifications of histone H3. Such 
modifications represent prime targets for deregulation in 
cancer and/or aging [4, 5, 32, 33]. Depleted levels of 
phosphorylated S10 of histone H3 by ~3 fold were 
observed 24h following transfection with E7 siRNA and 
by 48h histone H3 S10P was barely detectable (Figure 
2A, left panel and 2D). Thus HPV16 E7 appears, 
directly or indirectly, to increase global histone H3 S10 
phosphorylation. In contrast, levels of S10P H3 were 
unchanged 24h following transfection with E6 siRNA 
(Figure 2A, right panel and 2D). However, a decrease 
was observed by 48h and 72h and inversely correlated 
with increasing p53 levels (Figure 2D). Since p53 
decreases global histone H3 S10P [4, 34] the observed 
decrease in histone H3 S10P following HPV E6 RNAi 
is likely to be attributable to p53 induction. Levels of 
acetylated K18 of histone H3 also fell in response to E7 
silencing (Figure 2A, left panel) but did not change in 
response to E6 silencing (Figure 2A, right panel). Thus 
histone H3 K18 acetylation levels are selectively up-
regulated by HPV E7. The changes in S10P and K18Ac 
of histone H3 precede apoptosis in HPV E7-depleted 
cells (Figure 2A, Figure 2C for sub-G1 content; see also 
[30]). Phosphorylation of histone H2AX at S139 is 
associated with apoptotic events [35] and levels peaked 
transiently 48h post-transfection with E7 siRNA (Figure 
2A) co-incident with the onset of apoptosis ([30]; 
Figure 2C and data not shown). There was no change in 
histone H2AX following RNAi-mediated silencing of 
HPV E6 (Figure 2A).  
 
Acetylated K9 and K14 histone H3 levels were very 
low in SiHa cells and no change was detected following 
transfection with either E6 or E7 siRNA (data not  
shown). Treatment with trichostatin A, a class I and II 
histone deacetylase inhibitor, induced a dramatic 
increase in both K9Ac and K14Ac of histone H3 (data 
not shown) indicating high deacetylase activity at these 
sites in SiHa cells. Neither E6 nor E7 significantly 
affected K9 methylation of histone H3 in SiHa cells 
(Figure 2A). 
 
HPV E7 maintains elevated survivin levels in 
cervical cancer cells 
 
To explore how E7 silencing might decrease S10P we 
examined levels of aurora B and survivin. Aurora B is 
the principal histone H3 S10 kinase in human cells [36] 
and its activity is regulated by survivin [37]. Aurora B 
protein levels did not change in response to E7 silencing 
(Figure 2B). Interestingly, however, E7 silencing 
depleted survivin protein levels ~5 fold by 24h post-
transfection (Figure 2B and 2D), with little, if any, 
detectable protein by 48 and 72h.  These results identify 
survivin as a cellular target of HPV16 E7 and suggest 
that E7 can, directly or indirectly, upregulate survivin 
expression and/or stabilise survivin protein.  
 
In the mouse model for BRCA1 tumor suppressor 
function there is evidence that wild type BRCA1 
suppresses survivin expression via SIRT1-dependent 
epigenetic modification of histone H3 [38]. Our own 
future studies will determine if, in human cervical 
cancer, HPV16 E7 impacts upon survivin expression via 
a SIRT1-dependent mechanism. This will be 
particularly interesting given our discovery that HPV 
E7 up-regulates SIRT1 protein levels in human cervical 
cancer SiHa cells (see below). 
 
E6 silencing caused a delayed reduction in survivin 
protein levels (Figure 2B and 2D). The decrease in 
survivin in response to E6 silencing was inversely 
correlated with p53 protein levels, suggesting that this 
effect is mediated by p53 (Figure 2D) [39-41]. Lamin 
A/C silencing, a negative control, had no effect on 
survivin protein levels (data not shown). 
 
HPV E7 up-regulates survivin mRNA whilst aurora 
B sustains survivin protein levels 
 
HPV E7 silencing also resulted in reduced mRNA 
levels of survivin (Figure 2E) indicating that HPV E7 
increases host cell survivin transcription and/or mRNA 
half-life. Interestingly, although aurora B had no effect 
on survivin mRNA levels (Figure 2E) it appeared to 
sustain survivin protein levels (Figure 2F). It is possible 




















































Growth effects of survivin and aurora B in SiHa 
cells 
 
Survivin knockdown in SiHa cells resulted in reduced 
cell growth but failed to induce apoptosis (Figure 3A, 
3B; data not shown). Progressive reduction in G1 cells 
from ~60% to ~11% was observed 72h post-transfection 





















































Methods) and cells accumulated in G2/M. There was 
also a significant increase in the proportion of cells with 
>G2/M DNA content (Figure 3C, dotted circle; and 3D), 
suggesting that a proportion of the G2/M cells are still 
cycling but had failed to undergo cytokinesis. Indeed, 
two or more nuclei were visible in many of the enlarged 
cells resulting from transfection with survivin siRNA 
(Figure 3D).  
 
 
















































HPV16 E7 up-regulates SIRT1 protein levels in 
cervical cancer cells 
 
Previously we have shown that SIRT1 acts as a cancer-
specific survival factor in a range of epithelial cancer 
cell lines [20]. This raised the possibility that SIRT1 





















































[30]. Moreover SIRT1 protein levels are abnormally 
elevated in a range of human epithelial cell lines, 
including SiHa cervical cancer cells [25]. We now 
demonstrate that RNAi-mediated silencing of HPV E7 
in SiHa cells down-regulates SIRT1 protein levels by 
~50% 48h post-transfection with E7 siRNA (Figure 4A 
and 4B). In these same cells the levels of the pro-
 
 
www.impactaging.com            321                                     AGING, March 2009, Vol.1 No.3
apoptotic E3 ligase Itch and anti-apoptotic c-FLIP (c-
FLIPS and c-FLIPL) were unaffected by HPV E7 knock-
down (data not shown) demonstrating that the reduction 
in SIRT1 protein levels reflects a selective effect of HPV 
E7 depletion. In contrast to HPV E7 depletion, the 


















































protein (Figure 4A and 4B).  We conclude that HPV E7, 
but not HPV E6, is required to maintain the abnormally 
high levels of SIRT1 protein characteristically observed 
in SiHa cervical cancer cells. Our results thus identify the 
longevity protein SIRT1 as a novel cellular target of the 



















































levels.  (A)  Equal  amounts  of  protein  analysed  by 
immunoblotting  as  indicated,  upper  panels  SiHa 
cells  (50  μg  protein).  Bottom  panel  HCT116  cell
positive  control  for  p53  K382Ac  detection  (40  μg 
protein, 2 minute exposure). Note that p53 K382Ac 
is undetectable  in  SiHa  cells  (5 min exposure)  and 
requires 2 h exposure for detection (†). (B) Relative 
levels of SIRT1, SIRT1 S47P and SIRT1 S27P 48h post‐
transfection  with  indicated  siRNAs,  mean  of  two 
experiments. (C) Phase contrast images of SiHa cells
post‐transfection  with  the  indicated  siRNAs.  (D) 
Apoptotic SiHa cells 48h post‐transfection with  the 
indicated  siRNAs.  (E) Primary human  keratinocytes 
48h  post‐transfection  with  expression  vectors  for 
HPV  E6  and  HPV16  E7  and  equivalent  samples 
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The expression of SIRT1 in mammalian cells is subject 
to multiple control mechanisms operating at the levels 
of transcription, transcript half-life, translation and 
protein half-life [13, 25, 26, 43]. In the present study we 
found that depletion of HPV E7 in SiHa cells had no 
significant effect on SIRT1 mRNA levels (data not 
shown) suggesting that the effect of HPV E7 on SIRT1 
protein expression levels is post-transcriptional. 
Recently, we have reported that SIRT1 protein stability 
in human colorectal cancer cells (HCT116) is dependent 
upon JNK2 and is linked with SIRT1 phosphorylation at 
S27 [25]. A similar effect may contribute to the 
enhanced level of SIRT1 in SiHa cervical cancer cells 
since HPV E7 silencing caused ~ 80% reduction in 
SIRT1 S27P, whereas levels of SIRT1 phosphorylation 
at a second site, S47, paralleled the decrease in total 
SIRT1 (Figure 4A and 4B).  
 
Depletion of SIRT1 in SiHa cells induces apoptosis 
 
Depletion of SIRT1 in SiHa cells induced apoptosis 
(Figure 4C and 4D) demonstrating that cellular SIRT1 
enables SiHa cervical cancer cell survival. This is 
consistent with our previous observation that SIRT1 
functions as a cancer-specific survival factor in a range 
of human epithelial cancer cell lines [20]. Our present 
results indicate that HPV E7-dependent elevation of 
SIRT1 protein levels plays an essential pro-survival role 
in human cervical cancer cells. SIRT1-mediated 
suppression of apoptosis would thus explain the 
survival function of HPV E7 in SiHa cells (this work 
and Ref. 30). Moreover, since SIRT1 is an NAD-
dependent de-acetylase with multiple cellular targets, 
the discovery that HPV E7 up-regulates SIRT1 protein 
levels identifies a new mechanism by which HPV can 
access diverse SIRT1-dependent regulatory systems in 
human cervical keratinocytes.  
 
Exogenous expression of HPV E7 increases SIRT1 
protein levels in primary human keratinocytes 
 
The above results strongly indicate that HPV E7 in 
some way targets the cellular SIRT1 protein and 
maintains its expression at abnormally high levels in 
cervical cancer cells. The effect is specific for HPV E7 
since no effects on SIRT1 were observed following 
RNAi-mediated silencing of HPV E6 under identical 
conditions (see above). The HPV E7 effect on SIRT1 
could be a late event in the process of malignant cell 
transformation by the HPV virus. Alternatively HPV 
E7-mediated up-regulation of SIRT1 might play a 
causative role in malignant cell transformation. In 
favour of the latter alternative we show that SIRT1 
suppresses apoptosis in SiHa human cervical cancer 
cells (SiHa; Figure 4C and 4D).  
If HPV E7-mediated up-regulation of SIRT1 plays a 
causative role in malignant cell transformation we 
reasoned that this effect should be detected as an early 
event in the process of keratinocyte transformation. To 
test this primary human keratinocytes were exposed to 
high level HPV E7 expression: i.e. as occurs following 
integration of the HPV viral genome into host cell 
chromatin during malignant transformation in vivo. For 
this purpose we constructed individual expression 
vectors using HPV E6 and HPV E7 freshly cloned from 
the SiHa cells employed throughout this study (see 
Materials and Methods). Primary human keratinocytes 
were transfected with HPV E6 or HPV E7 expression 
vectors and exogenously expressed E6 and E7 proteins 
were detected by immunoblotting (Figure 4E). Samples 
were also probed for SIRT1 protein, SIRT1 S27P and 
SIRT1 S47P (in SiHa cells SIRT1 protein is 
phosphorylated at both S27 and S47; [25]).  
 
The results clearly show that SIRT1 protein levels 
increase dramatically within 48h expression of 
exogenous HPV E7. We have previously noted lack of 
detectable SIRT1 S27 and S47 phosphorylation in 
primary human keratinocytes [25] and this is confirmed 
here (Figure 4E). However both S27P and S47P became 
detectable following exogenous expression of HPV E7. 
This may simply reflect a detection threshold or, 
alternatively, be mechanistically linked with SIRT1 
protein accumulation (S27P correlates with SIRT1 
protein half-life in HCT116 colorectal cancer cells) 
[25]. It is also possible that SIRT1 protein accumulation 
in response to HPV E7 involves its relocation within the 
cell, and/or novel protein-protein interactions, and/or 
other post-translational modifications such as 
sumoylation. Further studies are required to elucidate 
the mechanism of SIRT1 protein accumulation in 
response to HPV E7. 
 
In contrast to HPV E7 the exogenous expression of 
HPV E6 failed to induce a change in SIRT1 protein 
level in primary human keratinocytes (Figure 4E; 
although p53 levels were depleted, data not shown). 
Thus increased SIRT1 protein expression levels induced 
by HPV E7 (i) cannot be attributable to a cellular stress 
response induced by expression of a foreign, viral 
protein, and (ii) cannot be induced by HPV E6.  
 
We therefore conclude that HPV E7 selectively induces 
increased SIRT1 protein levels and that this occurs 
within 48h of exogenous E7 expression in primary 
human keratinocytes. Conversely, in SiHa cells 
naturally expressing HPV E7 via the integrated HPV 
viral genome, E7 silencing induces a decrease in SIRT1 
protein. Thus our overall results indicate that HPV E7 
positively regulates SIRT1 protein levels and that 
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SIRT1 functions as a down-stream mediator of HPV E7 
in sustaining malignant cell survival.  
 
A new model for cell transformation by HPV E6 and 
E7 
 
Previous studies have presumed that HPV E6 is the 
major survival determinant in human cervical cancer 
and this concept has directed anti-cancer pharmaceutical 
research towards identification of agents that block the 
functions of HPV E6. This has been a reasonable 
presumption given that HPV E6 targets the p53 tumour 
suppressor protein. However, our own previous [30] 
and present observations indicate that up-regulation of 
p53 following HPV E6 silencing is not sufficient to 
induce apoptosis in human cervical cancer cells despite 
induction of cell growth arrest.  HPV E7 silencing, on 
the other hand, induces apoptosis. Apoptosis of HPV 
E7-silenced SiHa cells proceeds despite the continued 
suppression of p53 by HPV E6 ([30, 44] and Figure 5 
schematic). The ability of HPV E7 to up-regulate 
SIRT1 expression now provides a mechanistic 
explanation for this effect since SIRT1 is anti-apoptotic 
in epithelial cancer cells (Figure 5).   
 





























plains the attenuated functioning of p53 following 
selective HPV E6 depletion since the acetylation status 
of p53 under these conditions is low (Figure 4A; p53 
K382Ac), consistent with its deacetylation by 
abnormally high levels of the SIRT1 de-acetylase 
(maintained by HPV E7; Figure 5). HPV E6 silencing 
nonetheless permitted up-regulation of the p53 target 
gene p21 ([30]; Figure 1D and 2D) and this would 
account for the cell growth arrest induced by selective 
silencing of HPV E6 in SiHa cells [30] (see Figure 5).  
 
SIRT1 can function as a cancer-specific survival factor 
in cell lines derived from human epithelial and other 
cancers. Here we report that SIRT1 is targeted for up-
regulation by the viral oncoprotein HPV E7. It is well 
established that HPV E6 and E7 function as co-
operating onco-proteins and drive malignancy in 
cervical epithelial cells. Based on our present 
observations we suggest a new model for this co-
operation (Figure 5) in which targeting of cellular p53 
and SIRT1 by HPV E6 and E7 respectively enable dual 
access to the regulatory machinery normally involved in 
cellular homeostasis and chromosomal stability. In this 
way high risk HPV types subvert the SIRT1/p53 
regulatory machinery from the process of aging to the 



























Figure  5.  Model  for  the  respective  effects  of  HPV  E6  and  HPV  E7  on  human  cervical  cancer  cell  survival  and
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MATERIALS AND METHODS 
 
Cell lines. SiHa and CaSki cell lines contain the HPV16 
viral episome stably integrated into the host cell genome 
and were maintained and subcultured as described [30]. 
SiHa contain 1-2 integrated copies of the HPV16 
episome per cell; CaSki have ~600 integrated copies per 
cell. Primary human keratinocytes were cultured in 
defined keratinocyte media (Gibco) with appropriate 
supplements. 
  
siRNA transfection. Cells were transfected with HPLC-
purified synthetic siRNAs (Qiagen) formulated into 
liposomes as described [20, 30, 45, 46]. E6 and E7 
siRNA sequences were as follows: E6 siRNA = 5'-
GAGGUAUAUGACUUUGCUU(dTdT)-3'; E7 siRNA 
= 5'-AGGAGGAUGAAAUAGAUGG(dTdT)-3' as pub-
lished [30]. E6b siRNA = 5'-GUUACCACAGUUAUG 
CACA(dTdT)-3'; E6c siRNA = 5'-AUCAUCAAGAAC 
ACGUAGA(dTdT)-3'; E7b siRNA = 5'-CAGAGCCCA 
UUACAAUAUU(dTdT)-3'. Other siRNA sequences 
were: survivin siRNA = 5'-GAGCCAAGAACAAAAU 
UGC(dTdT)-3'; aurora B siRNA = 5'-GGUGAUGGAG 
AAUAGCAGU(dTdT)-3', Itch siRNA = 5'-CCACAAC 
ACACGAAUUACA(dTdT)-3',  c-FLIP siRNA = 5'-
GCAGUCUGUUCAAGGAGCA(dTdT)-3'. Lamin A/C 
and SIRT1 siRNA sequences were as published [20]. 
Selectivity of the siRNAs and efficiency of silencing 
was confirmed as described previously [20, 25, 30, 45, 
46].  
 
E6 and E7 cDNA cloning and exogenous expression. 
Mammalian expression vectors for HPV16 E6 and 
HPV16 E7 were generated by subcloning HPV16 E6 
cDNA or E7 cDNA, freshly cloned from low passage 
SiHa cells, into the multiple cloning site of pcDNA3.1. 
Generated constructs were verified by sequencing. 
DNA transfection was performed using lipofectamine 
(Invitrogen) according to the manufacturer’s 
instructions as previously described [25].  
 
mRNA quantification. Total cellular RNA was isolated 
using RNeasy kit (Qiagen) [46]. 100ng RNA was used 
for RT-PCR using Qiagen 1-Step RT-PCR kit or 50ng 
RNA for quantitative real-time RT-PCR on a DNA 
Engine Opticon2 system (MJ) using Quantitect SYBR 
Green RT-PCR kit (Qiagen). For survivin mRNA 
amplification primers 5'-GCATGGGTGCCCCGACGT 
TG-3' and 5'-TCAATCCATGGCAGCCAGCTG-3' 
were used in the thermal cycle: 500C for 30min; 950C 
for 15 min; 30 cycles of 940C for 30 sec, 580C for 45 
sec, 720C for 1 min; followed by 720C for 5 min. For 
aurora B, primers 5'-ACAGACGGCTCCATCTGGCCT 
-3' and 5'-TCAGGCGACAGATTGAAGGGCA-3' were 
used in the thermal cycle: 500C for 30min; 950C for 15 
min; 50 cycles of 940C for 30 sec, 580C for 45 sec, 720C 
for 1 min; and then 720C for 5 min. Cycle parameters 
and primers for HPV E6, HPV E7, SIRT1 and lamin 
A/C mRNAs were as previously described [20, 30].   
 
Immunoblotting. Total cell extracts were prepared from 
transfected cells [4] and equivalent amounts resolved by 
15% SDS-PAGE and electroblotted onto nitrocellulose 
for immunoblotting. Antibodies used to detect specific 
post-translational histone modifications were: anti-
phospho S10 H3 (Cell Signalling), anti-acetyl K18 H3 
(Cell Signalling), anti-acetyl K9 H3 (Upstate 
Technology), anti-acetyl K14 H3 (Upstate), anti-
dimethyl K9 H3 (Upstate) and anti-phospho S139 
H2AX (Upstate). Other antibodies used were: anti-
HPV16 E6 (ab70, Abcam), anti-HPV16 E7 (ED17, 
Santa Cruz), anti-p53 (DO1, Santa Cruz), anti-
acetylated K382 p53 (Cell Signalling), anti-SIRT1 
(Abcam), anti-S27P SIRT1 (Cell Signalling), anti-S47P  
SIRT1 (Cell Signalling), anti-survivin (NB500-201, 
Novus Biologicals), anti-aurora B (BD Biosciences), 
anti-p21 (BD), anti-RB (G3-245, BD), anti-lamin A/C 
(636, Santa Cruz), and anti-actin (MAB1501, 
Chemicon). Actin was used as a loading reference 
control in all experiments.  Visualisation of bound 
antibody was by enhanced chemiluminescence (Roche). 
The intensity of bands was quantitated by densitometry 
using Quantity One software (Biorad) as previously [4]. 
Comparative analyses shown in Figure 2 employed data 
obtained from equivalent exposures with the selected 
antibody (eg. S10P, survivin). We thank Dr Jack Ford 
for the K382Ac antibody control (Figure 4A, bottom 
panel). 
 
Cell cycle analysis and quantitation of apoptosis. Cell 
cycle analysis, and cell aggregate discrimination and 
histogram deconvolution using Cylchred software, were 
as previously described [4, 20, 45, 46]. Apoptotic cells 
were identified by flow cytometry using Annexin V-
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